Journal Scans
Long-Term Prognostic Significance of Early Molecular Response to Imatinib in Newly Diagnosed Chronic Myeloid Leukemia: An Analysis From the International Randomized Study of Interferon Versus STI571 (IRIS)
CML Prognosis With Early Molecular Response to Imatinib
TP Hughes, A Hochhaus, S Branford, MC Müller, JS Kaeda, L Foroni, BJ Druker, F Guilhot, RA Larson, SG O'Brien, MS Rudoltz, M Mone, E Wehrle, V Modur, JM Goldman, JP Radich
20100702
2010 Aug 2
Blood
Long-Term Prognostic Significance of Early Molecular Response to Imatinib in Newly Diagnosed Chronic Myeloid Leukemia: An Analysis From the International Randomized Study of Interferon Versus STI571 (IRIS)
Blood. 2010 Aug 2;[Epub Ahead of Print], TP Hughes, A Hochhaus, S Branford, MC Müller, JS Kaeda, L Foroni, BJ Druker, F Guilhot, RA Larson, SG O'Brien, MS Rudoltz, M Mone, E Wehrle, V Modur, JM Goldman, JP Radich
TAKE-HOME MESSAGE
Abstract
Abstract
This study examines the prognostic significance of early molecular response using an expanded dataset in chronic myeloid leukemia patients enrolled in IRIS. Serial molecular studies demonstrate decreases in BCR-ABL transcripts over time. Analyses of event-free survival (EFS) and time to progression to accelerated phase/blast crisis (AP/BC) at 7 years were based on molecular responses using the international scale (IS) at 6-, 12-, and 18-month landmarks. Patients with BCR-ABL transcripts > 10% at...
